Flunarizine-pizotifen single-dose double-blind cross-over trial in migraine prophylaxis.
The results of a double-blind cross-over clinical trial involving 27 patients with classical or common migraine are described to compare the prophylactic effect of the calcium entry blocker flunarizine with that of pizotifen. Duration of the treatment was two months, with an evening single-dose administration of both drugs. For most parameters, there was no definite difference between flunarizine and pizotifen in migraine prophylaxis. It has been demonstrated previously that pizotifen is an effective drug in migraine prophylaxis, and these results suggest that flunarizine is effective, too. Weight gain as a side effect was less frequent and less severe with flunarizine than with pizotifen; other side effects showed the same incidence with both drugs.
D002121:Calcium Channel Blockers / Q000008:administration & dosage / Q000627:therapeutic use*; D002936:Cinnarizine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005444:Flunarizine; D006801:Humans; D008881:Migraine Disorders / Q000517:prevention & control*; D010918:Pizotyline / Q000008:administration & dosage / Q000627:therapeutic use*; D013876:Thiophenes / Q000627:therapeutic use*; D013997:Time Factors
D002121:Calcium Channel Blockers; D013876:Thiophenes; D010918:Pizotyline; D002936:Cinnarizine; D005444:Flunarizine